<DOC>
	<DOCNO>NCT02120222</DOCNO>
	<brief_summary>This phase I clinical trial study side effect selinexor treat patient melanoma remove surgery . Drugs use chemotherapy , selinexor , may stop growth tumor cell , stop dividing .</brief_summary>
	<brief_title>Evaluating SINE KPT-330 Treating Patients With Melanoma That Can Be Removed By Surgery</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To estimate safety KPT-330 ( selinexor ) patient melanoma maximum tolerate dose ( MTD ) define phase 1 study . SECONDARY OBJECTIVES : I . To determine clinical benefit rate ( CBR ) ( complete response , partial response , stable disease ) patient unresectable melanoma . II . To assess efficacy MTD measure progression free survival ( PFS ) patient melanoma . TERTIARY OBJECTIVES : I . To validate nuclear transport inhibition result treatment . II . To assess v-raf murine sarcoma viral oncogene homolog B1 ( BRAF ) , neuroblastoma RAS viral ( v-ras ) oncogene homolog ( NRAS ) , platelet-derived growth factor receptor , beta polypeptide ( PDGFRB ) mutational status impact response . III . To assess alteration signal pathway result therapy KPT-330 . IV . To assess immunologic change result treatment KPT-330 . OUTLINE : Patients receive selinexor orally ( PO ) twice weekly ( BIW ) . Courses repeat every 4 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 year</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Written inform consent accordance federal , local , institutional guideline Patients unresectable melanoma Patients must receive biologic therapy ( e.g . interleukin 2 ) BRAF and/or MEK inhibitor ( tumor contain V600E V600K mutation ) 628 metastatic disease . If patient receive agent , rationale treat patient 629 agent must clear study PI ( ie V600e/k BRAF mutation patient autoimmunity , thus 630 eligible biologic therapy ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Total white blood cell ( WBC ) count &gt; = 3000/mm^3 Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 Platelet count &gt; = 100,000/mm^3 Bilirubin &lt; 2 time upper limit normal ( ULN ) ( except patient Gilbert 's syndrome must total bilirubin &lt; 3 time ULN ) Alanine aminotransferase ( ALT ) &lt; 2.5 time ULN ; case know ( radiological and/or biopsy document ) liver metastasis , ALT &lt; 5.0 time ULN acceptable Estimated creatinine clearance &gt; = 50 mL/min , calculate use formula Cockroft Gault Female patient childbearing potential must agree use dual method contraception negative serum pregnancy test screening , male patient must use effective barrier method contraception sexually active female childbearing potential ; acceptable method contraception condom contraceptive foam , oral , implantable injectable contraceptive , contraceptive patch , intrauterine device , diaphragm spermicidal gel , sexual partner surgically sterilize postmenopausal ; male female patient , effective method contraception must use throughout study three month follow last dose Patients pregnant lactate Radiation , chemotherapy , immunotherapy systemic anticancer therapy = &lt; 2 week prior initiation therapy Major surgery within four week initiation therapy Unstable cardiovascular function : Symptomatic ischemia , Uncontrolled clinically significant conduction abnormality ( e.g . : ventricular tachycardia antiarrhythmic exclude 1st degree atrioventricular ( AV ) block asymptomatic leave anterior fascicular block [ LAFB ] /right bundle branch block [ RBBB ] exclude ) Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) class &gt; = 3 , Myocardial infarction ( MI ) within 3 month initiation therapy Uncontrolled active infection within one week prior first dose Known human immunodeficiency virus ( HIV ) seropositive Known active hepatitis A , B , C infection ; know positive hepatitis C virus ( HCV ) ribonucleic acid ( RNA ) HBsAg ( hepatitis B virus [ HBV ] surface antigen ) Patients active central nervous system ( CNS ) malignancy Asymptomatic small lesion consider active Treated lesion may consider inactive patient able taper steriods without recurrent neurologic symptom . Patients exclude major resection bowel could influence absorption , inflammatory bowel disease , gastrointestinal condition increase risk perforation , history abdominal fistula , gastrointestinal perforation within 28 day prior begin study treatment Grade &gt; = 2 peripheral neuropathy within 14 day prior initiation therapy History seizure , movement disorder cerebrovascular accident within past 5 year Patients know macular degeneration uncontrolled glaucoma In opinion investigator , patient significantly ideal body weight Serious psychiatric medical condition could interfere treatment Participation investigational anticancer study within 3 week prior initiation therapy Concurrent therapy approve investigational anticancer therapeutic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>melanoma</keyword>
</DOC>